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Abstract
L-Fucose and L-fucose-containing polysaccharides, glycoproteins or glycolipids play an important
role in a variety of biological processes. L-Fucose-containing glycoconjugates have been implicated
in many diseases including cancer and rheumatoid arthritis. Interest in fucose and its derivatives
is growing in cancer research, glyco-immunology, and the study of host–pathogen interactions.
L-Fucose can be extracted from bacterial and algal polysaccharides or produced (bio)synthetically.
While deuterated glucose and galactose are available, and are of high interest for metabolic studies
and biophysical studies, deuterated fucose is not easily available.
Here, we describe the production of perdeuterated L-fucose, using glyco-engineered Escherichia
coli in a bioreactor with the use of a deuterium oxide-based growth medium and a deuterated
carbon source. The final yield was 0.2 g L−1 of deuterated sugar, which was fully characterized
by mass spectrometry and nuclear magnetic resonance spectroscopy. We anticipate that the
perdeuterated fucose produced in this way will have numerous applications in structural biology
where techniques such as NMR, solution neutron scattering and neutron crystallography are widely
used. In the case of neutron macromolecular crystallography, the availability of perdeuterated
fucose can be exploited in identifying the details of its interactionwith protein receptors and notably
the hydrogen bonding network around the carbohydrate binding site.
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Introduction
The deuteration of biomolecules by stable isotope labeling is of
high interest for nuclear magnetic resonance (NMR) spectroscopy
and neutron scattering studies of the structure and dynamics of
biological macromolecules and is now widely used (Haertlein et al.
2016; Blakeley and Podjarny 2018). Tailor-designed deuteration can
be used very effectively in studies of multicomponent systems by
small-angle neutron solution scattering (Laux et al. 2008; Cuypers,
Trubitsyna, et al. 2013b; Dunne et al. 2017; Josts et al. 2018; Maric
et al. 2019) and neutron reflectometry (Grage et al. 2011; Hellstrand
et al. 2013; Waldie et al. 2018). In Laue neutron crystallography, the
use of perdeuterated protein imparts major benefits in terms of data
quality and interpretation (Haupt et al. 2014; Dajnowicz et al. 2017;
Yee et al. 2019; Kwon et al. 2020), and the same is true in the case
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of monochromatic neutron crystallography (Cuypers, Mason, et al.
2013a; Cuypers et al. 2016). Deuteration of small biomolecules has
wide application in analytical methods, with growing development
for the study of metabolism (Shimba et al. 1990) and in living cell
imaging techniques such as Raman microscopy (Wei et al. 2013).
MeV ion beam analysis techniques such as 3He Nuclear Reaction
Analysis (NRA), where high sensitivity to deuterium was utilized to
monitor the uptake of deuterated sugars in bacteria (Lowery et al.
2015) have also been deployed. More recently, it has been demon-
strated that deuteration of key hydrogen atoms at positions where
drugs are enzymatically metabolized for elimination has direct effects
on pharmacological properties of these substances by improving
their stability, and therefore their half-life, and by decreasing their
toxicities (Schmidt 2017). The basis of the increased stability of these
“heavy hydrogen drugs” is related to the stronger deuterium–carbon
bond making the drug more resistant to enzymatic modification
and elimination; deuteration of known drugs, referred to as the
“deuterium switch”, resulted in a boost of patenting of labeled drugs,
with several of them now in clinical trials (Timmins 2017). The first
approved deuterated drug for therapeutic use was deutetrabenazine,
and it has been used for the treatment of chorea in Huntington’s
disease (Dean and Sung 2018).
Proteins and lipids are generally obtained in their perdeuterated
form through the use of recombinant bacteria or yeasts (Meilleur
et al. 2009; Haertlein et al. 2016;Moulin et al. 2018). The availability
of perdeuterated and well-characterized glycans is more limited. For
selective deuteration, chemical synthesis of perdeuterated monosac-
charides has previously been described. Through the use of appropri-
ate protecting groups, direct H–D exchange reactions in the presence
of an activated carbon-supported platinum group catalyst were used
to produce a variety of deuterated monosaccharides (Koch and Stuart
1978; Sawama et al. 2012). Using biotechnology approaches, it has
been demonstrated more than 50 years ago that certain algae can
be adapted to grow in 99.6% D2O, resulting in the large-scale
production of perdeuterated glucose and mannose (Crespi et al.
1959; Chorney et al. 1960). It is only recently that cyanidin 3-O-
glucoside was produced with a perdeuterated glucose moiety using
recombinant Escherichia coli (Gupta et al. 2018). Polysaccharides
have been produced in bacteria, in the form of perdeuterated cellulose
(O’Neill et al. 2015) and perdeuterated heparin (Cress et al. 2019).
The current work focuses on l-fucose (6-deoxy-l-galactose),
which is a nonclassical monosaccharide with an l-configuration
correlated to unusual ring conformation, and a methyl group at C6.
l-Fucose (Fuc) is present in all living kingdoms, from giant viruses (De
Castro et al. 2013) to bacterial polysaccharides and plant cell walls. In
mammals, it is a common component of glycolipids and glycoproteins
(Vanhooren and Vandamme 1999; Schneider et al. 2017). Terminal
fucosylation of oligosaccharides creates bioactive epitopes, such as
the histo-blood group oligosaccharides (ABO and Lewis epitopes)
(Painter et al. 1965). Human milk oligosaccharides are also rich
in terminal fucose residues, which serves as a receptor analogue
for pathogens, and a modulators of immune responses (Bode
2015). Fucose is therefore of interest as a biomarker for some cancers
as well as a target for pathogen receptors (Heggelund et al. 2017).
The production of perdeuterated fucose, l-fucose-d12 (Fuc-
d12), is therefore of high interest. The chemical approach has been
described but is complex and time-consuming (Koch and Stuart
1978; Sawama et al. 2012). An alternative approach is based on the
production of “recombinant” oligosaccharides in microorganisms,
by engineering their metabolic pathways. This area of research was
initiated at the end of the last century with the production of chito-
oligosaccharides in E. coli (Samain et al. 1997). During the last
decades, a large number of oligosaccharides have been produced
using this approach, including human milk oligosaccharides that
are of high commercial interest for improving infant formula milk
(Priem et al. 2002). For example, α-2′-fucosyllactose, a major
trisaccharide of human milk, has been obtained by introducing the
FUT2 gene from Helicobacter pylori into E. coli (Albermann et al.
2001; Drouillard et al. 2006; Yu et al. 2018). This trisaccharide can
serve as a substrate for a fucosidase. With appropriate engineering
of microorganisms, fucose can be recombinantly produced, as
demonstrated in Saccharomyces cerevisiae (Liu et al. 2018) and then
in E. coli (Liu et al. 2019).
In this work, the production of perdeuterated Fuc-d12 (per-C-
deuterated Fuc-d8 when dissolved in H2O) is described. Based on the
previous construct for production of α-2′-fucosyllactose (Drouillard
et al. 2006), the metabolic pathways of the previously described E.
coli strain were further engineered with the addition of the appro-
priate hydrolase and removal of sugar transporter. After adaptation
of the strains for cultivation in an appropriate deuterated medium,
a large amount of perdeuterated fucose was produced and fully
characterized.
Results
The fucose-producing strain
A schematic diagram of the production of l-fucose using the engi-
neered FUC5 strain is shown in Figure 1. FUC5 is a derivative of
the E. coli K12 strain DH1, with genetic modifications for overex-
pression of genes involved in GDP-fucose production, introduction
of 2-fucosyltransferase gene fromH. pylori and fucosidase gene from
Bifidobacterium bifidum strain JCM1254, and deletion of genes
involved in the metabolism of lactose. In addition, several genes have
been knocked out to optimize the production of fucose: the fucI gene
(coding for fucose isomerase) to prevent isomerization to fuculose
and the fucP gene (fucose permease) to prevent internalization of
extracellular fucose. A detailed list of the plasmids, genes and E. coli
strains described in this work can be found in Table I.
Adaptation to D2O and batch fermentation
In order to compare fucose production in different conditions, the
FUC5 strain was grown in both unlabeled and deuterated minimal
medium supplemented with hydrogenated glycerol and deuterated
glycerol-d8, respectively. Its growth was stepwise adapted to deuter-
ated media as previously described (Haertlein et al. 2016). Both
hydrogenated and deuterated fucose were produced in simple batch
fermentations. The hydrogenated culture showed a higher growth
rate in the exponential phase, reaching a maximum OD600 of 26,
73 h after inoculation. The deuterated culture showed a similar lag
phase profile but slower growth in the exponential phase with the
highest OD600 being 17, 112 h after the start of the fermentation
(Figure 2A).
The bacterial growth and the deuterated fucose concentration
showed a cell-density-associated production pattern (Figure 2). A
maximum Fuc-d12 concentration of 0.20 g L
−1 was obtained by the
end of the fermentation process. The yield of fucose produced per
gram of carbon source in the growth medium was 10-fold lower
for the deuterated culture (0.2 vs. 2.1 g L−1, see Figure 2B and C)
when supplied with the same quantity of carbon source, i.e., 30 g
of glycerol used per liter of growth medium as indicated in the
experimental section. Analysis by thin layer chromatography (TLC)
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Fig. 1. Schematic representation of the metabolic network for fucose production using the engineered E. coli FUC5 strain. Inserted genes are shown in italics
and knockout genes are indicated with crosses in the diagram.
Table I. Genes, plasmids and E. coli strains used in this study
Description Reference or source
Genes
futC α-1,2-fucosyltransferase from Helicobacter pylori strain
26695
GenBank KY499613
afcA α-1,2-fucosidase from Bifidobacterium bifidum strain
JCM1254
GenBank AY303700
gmd, wcaG,manC,manB E. coli genes coding GDP-Man dehydratase, fucose
synthase, GDP-Man pyrophosphorylase and
phosphomannomutase, respectively
GenBank U38473.1
Plasmids
pEXT20-futC pEXT20 carrying futC Drouillard et al. (2006)
pBP-futC Derived from pEX20-futC This study
pBBRGAB pBBR1MCS-3 derivative carrying gmd, wcaG,manC and
manB
Dumon et al. (2006)
pSU-fucase pSU2718 derivative carrying active α-1,2-fucosidase
domain of afcA from Bifidobacterium bifidum
This study
Strains
DC DH1 lacZ lacA Dumon et al. (2006)
FUC DC fucI fucP This study
FUC5 FUC (pBP-futC, pBBRGAB, pSU-fucase) This study
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Fig. 2. (A) Growth curves of hydrogenated and deuterated E. coli FUC5 in high cell-density cultures. The optical density was measured at 600 nm using a
spectrophotometer and was plotted against time (h). (B, C) Production of hydrogenated (B) and deuterated (C) fucose using the genetically modified E. coli FUC5.
The concentrations of extracellular and intracellular fucose were measured spectrophotometrically using the K-Fucose kit (Megazyme). Symbols represent a
mean value of two independent measurements. Error bars indicate the standard deviation (NB some of the error bars are smaller than the symbol size used in
the panels).
Fig. 3. (Top) Mass spectrometry and (Bottom) chromatography analyses of per-C-deuterated fucose produced. Analyses were carried out in H2O and thus
correspond to Fuc-d8. Bottom: size-exclusion chromatography (SEC) profiles of the saccharides present in the extracellular fraction of the fucose-producing
strain after batch fermentation in deuterated media: (a) lactose, (b) deuterated fucose and (c) isopropyl-β-D-thiogalactopyranoside (IPTG) in the black line,
superimposed with a SEC profile of standard solutions in grey lines. Top: only the positive electrospray ionization (ESI) mass spectrum of the deuterated fucose
(Fuc-d8) is displayed with sodium and potassium adduct ions atm/z 196 and 211, respectively.
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showed gradually increasing concentrations of intracellular lactose
transported from the medium to the cells by lactose permease. The
TLC also revealed the increase in concentration of extracellular
fucose over time (Figures S1 and S2).
Optimization of purification method
Deuterated fucose was purified directly from the crude extracellular
fraction. After the first ion-exchange chromatography purification
step, TLC analysis showed the presence of lactose and isopropyl-
β-d-thiogalactopyranoside (IPTG) that were added to the minimal
medium during high cell-density culture. Further fractionation of
these compounds was achieved by size-exclusion chromatography
(SEC) using a TOYOPEARL HW-40 column made of hydroxylated
methacrylic polymer (Figure 3, Bottom). This technique was used as
a polishing step to efficiently separate lactose, fucose and IPTG, three
molecules of similar sizes that could be eluted as separate single peaks.
After purification, 220 mg of lyophilized Fuc-d12 was obtained from
a culture using 1.5 L of D2O and 45 g of deuterated glycerol.
Deuterated fucose characterization
The metabolic incorporation of deuterium in the fucose molecule
was examined and demonstrated by electrospray ionization (ESI)
mass spectrometry and quantified by 1H NMR. The results (Figure 3,
Top) showed that the purified product dissolved in a water/methanol
solution generated two major peaks corresponding to the exact
masses of sodium adduct ions [M + Na]+ and potassium adduct ions
[M + K]+ at m/z values of 195 and 211, respectively, confirming the
presence of per-C-deuterated l-fucose (Fuc-d8).
The extent of deuteration of the fucose ring and themethyl carbon
was also verified by 1H and 2H NMR. Proton NMR spectra were
measured on samples of commercially available hydrogenated l-
fucose and on the deuterated l-fucose produced in this work, both
solubilized in D2O. The deuterium NMR spectrum was measured
from the deuterated fucose dissolved in water. The 1H spectrum of the
purified compound exhibited the loss of intensity of all proton signals
compared to the non-labeled standard (Figure 4). Moreover, the
deuterium signals observed in the 2H spectrum of the perdeuterated
product demonstrated that deuterium replacement has taken place
successfully for all of the carbon atoms of the fucose molecule.
Discussion
In this study, glyco-engineered E. coli has been used to produce
deuterated fucose from deuterated glycerol and D2O via biosynthetic
pathways. For the production of deuterated fucose-d12, deuterated
glycerol-d8 was used as the sole carbon source. Even though glucose
is a preferred carbon source for E. coli, several studies showed
that engineered E. coli strains producing fucosyllactose and fucose
give higher titers of fucose when grown on glycerol (Jung et al.
2019; Liu et al. 2019). Compared with the hydrogenated culture, the
perdeuterated high cell-density culture grew more slowly in the expo-
nential phase and gave lower titers of fucose. Similar behavior has
been observed in deuteration of organic molecules using engineered
organisms (Meilleur et al. 2009; Moulin et al. 2018).
The engineered FUC5 strain produced 0.2 g L−1 of deuterated
fucose from a limited amount of glycerol in a simple batch fermen-
tation. The fully deuterated fucose was characterized by mass spec-
trometry, proton and deuterium NMR, confirming full deuteration
of the final product. It should be noted that the final yield of both
the hydrogenated and the perdeuterated monosaccharides in this
study was strongly dependent on the amount of glycerol used during
the fermentation process. Due to the cost of the deuterated carbon
source, this amount was limited to 45 g in both the H- and the D-
studies. Under optimal hydrogenated conditions where the quantity
of carbon source was not limited, the highest titer of fucose obtained
was 20 g L−1 (data not shown).
Perdeuteration using engineered E. coli is therefore a convenient
and effective method for a high-quantity production of fully deuter-
ated simple and more complex sugars for use in neutron scattering
experiments as well as in pharmacokinetic studies. In a first appli-
cation, Fuc-d12 will be used as a ligand for fucose-specific lectins in
single crystal neutron diffraction experiments.
Due to the larger and positive coherent scattering of deuterium
compared to hydrogen in neutron scattering experiments, there is a
better visibility of deuterium atoms vs. hydrogen. In this study, the 1H
atoms changed for deuterium (2H) atoms in the fucose molecule will
allow clearer visualization of crucial interactions between the sugar
and bacterial lectins, as well as an optimization of the overall quality
of the neutron data through the reduction of hydrogen incoherent
scattering.
Materials and methods
Strains and plasmid construction
The fucose-producing strain FUC5 was obtained by transforming the
host strain FUC with the three following plasmids: pBP-futC which
contains the α-1,2-fucosyltransferase gene futC fromH. pylori strain
26695; pBBRGAB which contains the four E. coli gmd,wcaG,manC
and manB genes coding GDP-Man dehydratase, fucose synthase,
GDP-Man pyrophosphorylase and phosphomannomutase, respec-
tively; and pSU-fucase which contains the sequence of the active
α-1,2-fucosidase domain of the afcA gene from B. bifidum strain
JCM1254 (Katayama et al. 2004).
The host strain FUC was designed from strain DC (Dumon
et al. 2006) by knocking out the genes fucI and fucP encoding
fucose isomerase and fucose permease, respectively. Strain DC was
a lacA lacZ null mutant derived from the E. coli K12 strain DH1
(DSM 4235). In order to knockout the fucPI genes, a 1.44 kb
segment located between nucleotides 913 of fucP and 998 of
fucI was deleted and replaced by the 5′AAGCTT sequence as
follows: two DNA segments flanking the deleted sequence were
amplified by PCR. The upstream 0.87 kb segment was amplified with
primers 5′GGATCCGTAGATAAAGATGCAGGGCAAAGCAGAAG
and 5′AAGCTTGGTTCCGGTTAAATAGTTAGCGGCAAAG, and
the downstream 0.81 kb segment was amplified with primers
5′AAGCTTCGTGGCGACCGAAAACGACAG and 5′CTCGAGAC-
CGGGCATCACATCAGGGAG. The two amplified fragments were
ligated at their terminal HindIII restriction site and cloned together
into the BamHI SalI sites of the suicide vector pKO3. The deletion
was then carried out according to the pKO3 gene replacement
protocol (Link et al. 1997).
The plasmid pBP-futC was designed from plasmid pEXT20-
futC (Drouillard et al. 2006) by removing the ampicillin gene using
DraI digestion and by inserting via blunt-end ligation a kanamycin
cassette, obtained by PstI digestion of the pUC4K vector.
The design of pSU-fucase plasmid was carried out as follows:
a 2.73 kb DNA fragment containing the sequence of the active α-
1,2-fucosidase domain of the afcA gene was amplified by PCR using
genomic DNA of B. bifidum strain JCM1254 as a template and the
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Fig. 4. 1H (Top andMiddle) and 2H (Bottom) NMR spectra comparing the signal intensity for hydrogenated L-fucose and deuterated L-fucose. Peaks in the dashed
boxes correspond to the hydrogen (1H spectra) and deuterium (2H spectrum) atoms of the fucose molecule. A signal of sodium succinate is observed at 2.4 ppm
for the 1H spectra.
following primers: 5′CTCGAGTAAGGAGGTAATATAATGGTCA-
TCGCCAGTGTCGAGGACG and 5′AAGCTTAGGCGCTCGCCT-
TCTTCGTGATCGTGTAC. The amplified fragment was first cloned
into pCR4Blunt-TOPO vector (Invitrogen) and then subcloned into
the XhoI andHindIII sites of the pSU2718 expression vector to form
pSU-fucase (Martinez et al. 1988).
Construction of pBBRGAB plasmid was previously described
(Dumon et al. 2006).
Production of deuterated fucose in batch fermentation
Precultures of the fucose-producing strain were first grown in LB
medium.All culturemedia were supplementedwith 15 μgmL−1 tetra-
cycline, 20 μg mL−1 chloramphenicol, 50 μg mL−1 kanamycin and
4 μg mL−1 thiamine. All cultures were grown at 28◦Cwith shaking at
160 rpm.The strain was adapted to deuterated minimal mediumwith
the following composition: 5 g L−1 NH4H2PO4, 5 g L−1 KH2PO4,
0.5 g L−1 C6H8O7 (citric acid), 1.65 g L−1 KOH, 0.65 g L−1 NaOH,
7.5 mL trace mineral solution [13 g L−1 N(CH2CO2H)3 (nitrilo-
triacetic acid), 7 g L−1 KOH, 7.5 g L−1 C6H5FeO7 (ferric citrate),
1.3 g L−1 MnCl2.4H2O,1.2 g L−1 ZnSO4.7H2O,0.25 g L−1 H3BO3,
0.15 g L−1 Na2MoO4.2H2O, 0.21 g L−1 CoCl2. 6H2O, 0.13 g L−1
CuCl2.2H2O] and 45 g glycerol-d8 (Eurisotop). A single colony of
E. coli FUC5 cells containing pBP-futC, pBBRGAB and pSU-fucase
plasmids grown overnight on LB agar plates supplemented with the
three antibiotics was used to inoculate 15mL of minimal medium and
was grown overnight at 28◦C. The culture was then used to inoculate
15 mL of 100% D2O minimal medium (with deuterated glycerol-
d8) at OD600 of 0.1 and grown overnight. This step was repeated
five times until the doubling time for E. coli reached values similar
to those for hydrogenated cultures. The last deuterated preculture
of 200 mL was used to inoculate the 1.5 L of deuterated minimal
medium in a 3 L bioreactor used for batch fermentation. The pH of
the culture medium was regulated at 7.2 by addition of 4% NaOD.
The temperature was maintained at 28◦C. The IPTG inducer and
lactose acceptor were added to a final concentration of 0.2 mM and
0.5 g L−1, respectively, at the inoculation time. The fermentation was
stopped after consumption of the deuterated glycerol-d8 from the
culture medium.
Analytical methods
Cell growth was monitored by measuring turbidity at 600 nm
(OD600) using a spectrophotometer. Culture aliquots (1 mL) were
taken at different time points throughout the high cell-density
culture. Samples were centrifuged and the supernatants treated as
the extracellular fraction. The pellets were resuspended in 1 mL of
Milli-Q water and boiled for 20 min at 100◦C. After centrifugation,
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the supernatants were treated as the intracellular fraction. Samples
were analyzed using thin layer chromatography on silica gels with
an eluent composed of 1-propanol–acetic acid–water in 2:1:1 ratio.
After dipping the plate in orcinol–sulphuric acid reagent, the spots
were visualized by heating at 100◦C.
Purification of deuterated fucose
At the end of the fermentation, the bacterial cells were recovered by
centrifugation (8000 g for 1 h at 8◦C). The supernatant containing
the deuterated fucose is referred to as extracellular fraction. The
purification was performed in two steps. The first step was carried
out using ion-exchange chromatography. The crude extracellular
fraction was treated with a strongly acidic cation-exchange resin
(Amberlite IR120 hydrogen form, Sigma-Aldrich). The resin was
added progressively until the pH dropped below 3. After decantation,
precipitated proteins were eliminated by centrifugation (16,000g
for 1 h at 8◦C). The supernatant was filtered and loaded onto
a column with a strongly acidic cation-exchange resin (DOWEX
50WX4 hydrogen form, Sigma-Aldrich) and immediately neutralized
by passing through a weakly basic anion-exchanger resin (DOWEX
66 free base, Sigma-Aldrich). The final eluate was colorless with neu-
tral pH. The purity and amount of fucose were analyzed by thin layer
chromatography. Fractions containing fucose were pooled together,
sterile filtered and lyophilized. The resulting mix was further frac-
tionated by size-exclusion chromatography using a semi-preparative
TOYOPEARL® HW-40 column (Tosoh Bioscience GmbH) equipped
with a refractive index detector (Knauer). The chromatography was
performed at ambient temperature with water as a mobile phase and
a flow rate of 120 mL h−1. Fractions containing pure product were
pooled together and submitted to three cycles of resuspension in D2O
and freeze-drying.
Quantification of hydrogenated and deuterated
L-fucose
Quantification of the intracellular and extracellular fucose was car-
ried out on the cell paste and crude supernatant samples, respectively,
using an enzymatic l-fucose assay kit (K-FUCOSE, Megazyme).
The assay is based on the oxidation of l-fucose to l-fucono-1,5-
lactone by l-fucose dehydrogenase in the presence of nicotinamide
adenine dinucleotide phosphate (NADP+). The amount of l-fucose
is stoichiometric to the production of reduced nicotinamide ade-
nine dinucleotide phosphate (NADPH), measured by an increase of
absorbance at 340 nm. The final amount of the deuterated fucose
obtained was quantified by weighing the lyophilized powder after
purification.
Structural analysis of deuterated fucose
Positive and negative ion ESI mass spectrometry data were recorded
on the Bruker amaZon speed ion trap mass spectrometer. A sample
of deuterated fucose was solubilized in D2O to a final concentration
of 50 μM.
The proton and deuterium NMR spectra were recorded with a
Bruker AvanceTM III NMR spectrometer operating at a frequency
of 400.13 MHz for 1H and 61.42 MHz for 2H. For the 1H NMR
experiments, samples of hydrogenated and deuterated fucose were
solubilized in D2O with 1.82 g L
−1 sodium succinate as a standard.
Residual signal of the solvent was used as the internal standard: HOD
at 4.8 ppm at 298 K. The 1H spectra were recorded at 298 K, with a
4006 Hz spectral width, 32,768 data points, 4.10 s acquisition times,
10 s relaxation delays and 16 scans.
The 2H NMR spectrum was measured on a sample of 7 mg of
deuterated fucose dissolved in H2O at pH 6.7. The
2H spectrum
was acquired at 298 K, without broadband 2H-decoupling, using a
90◦ pulse, 10,015 Hz sweep width, 3030 number of data points, 1 s
acquisition time and 1024 number of scans.
Supplementary data
Supplementary data for this article is available online at http://glycob.
oxfordjournals.org/.
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